Indirect health costs in ulcerative colitis and Crohn's disease: A systematic review and meta-analysis

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 15, Issue 2, 2015, Pages 253-266

  Kawalec, Paweł ^a   Malinowski, Krzysztof Piotr ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

absenteeism; cost of illness; Crohn's disease; economic burden; indirect cost; inflammatory bowel disease; presenteeism; systematic review; ulcerative colitis

Indexed keywords

ABSENTEEISM; CAPITAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; ECONOMIC ASPECT; EUROPE; HEALTH CARE COST; HUMAN; INFLAMMATORY BOWEL DISEASE; META ANALYSIS; NEW ZEALAND; NORTH AMERICA; PRESENTEEISM; PUBLICATION; REVIEW; SOCIOECONOMICS; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; WORK; WORK DISABILITY; COLITIS, ULCERATIVE; COST OF ILLNESS; ECONOMICS; STATISTICAL MODEL;

COLITIS, ULCERATIVE; COST OF ILLNESS; CROHN DISEASE; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMIC;

EID: 84924628456     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2015.1011130     Document Type: Review

References (32)

1. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369:1641-57
2. Farrell TJ, Peppercorn MA. Ulcerative colitis. Lancet 2002;359:331-40
3. Büsch K, Ludvigsson JF, Ekström-Smedby K, et al. Nationwide prevalence of inflammatory bowel disease in Sweden: a population-based register study. Aliment Pharmacol Ther 2014;39(1):57-68
4. Kawalec P, Mikrut A, Wis̈niewska N, et al. Tumor necrosis factor-A antibodies (infliximab, adalimumab and certolizumab) in Crohns disease: systematic review and meta-Analysis. Arch Med Sci 2013;9(5): 765-79
5. Kawalec P, Mikrut A, Lopuch S. Systematic review of the effectiveness of biological therapy for active moderate to severe ulcerative colitis. J Gastroenterol Hepatol 2014;29(6):1159-70
6. Nguyen GC, Tuskey A, Dassopoulos T, et al. Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004. Inflamm Bowel Dis 2007;13:1529-35
7. Krol M, Brouwer W. How to estimate productivity costs in economic evaluations. Pharmacoeconomics 2014;32(4):335-44
8. Thomas T, Cohen RD. Pharmacoeconomic considerations for inflammatory bowel disease in the era of biological therapies. Expert Rev Gastroenterol Hepatol 2007; 1(1):101-12
9. Zhao FL, Xie F, Hu H, et al. Transferability of indirect cost of chronic disease: a systematic review and meta-Analysis. Pharmacoeconomics 2013; 31(6):501-8
10. GDP per capita, PPP (current international $) World Development Indicators database. World Bank. Database updated on 16 December 2014. [Accessed on 20 December 2014]
11. Available from: http://handbook.cochrane. Org
12. Mandel MD, Bálint A, Lovász BD, et al. Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics. Eur J Health Econ 2014;15(Suppl 1):S121-8
13. Benedini V, Caporaso N, Corazza GR, et al. Burden of Crohns disease: economics and quality of life aspects in Italy. Clinicoecon Outcomes Res 2012;4:209-18
14. Juan J, Estiarte R, Colome E, et al. Burden of illness of Crohns disease in Spain. Dig Liver Dis 2003;35(12):853-61
15. Lion M, Gearry RB, Day AS, et al. The cost of paediatric and perianal Crohns disease in Canterbury, New Zealand. N Z Med J 2012;125(1349):11-20
16. Mesterton J, Jönsson L, Almer SH, et al. Resource use and societal costs for Crohns disease in Sweden. Inflamm Bowel Dis 2009;15(12):1882-90
17. Loftus EV, Gue-rin A, Tsaneva M, et al. Direct and Indirect Economic Burdens and Impact On Salary Growth of Moderate to Severe Crohns Disease. Gastroenterology 2009;136(5 Suppl 1):A26-7
18. Sandborn WJ, Colombel JF, Louis E, et al. Economic impact of deep remission in adalimumab-treated patients with Crohns disease: results from extend. Gastroenterology 2011;140(5 Suppl 1):S205
19. Cohen R, Rizzo J. Yang M at al. Direct and Indirect Utilization and Costs Associated with Ulcerative Colitis. Am J Gastroenterol 2012;107:S608-95
20. Stark R, Konig HH, Leidl R. Costs of inflammatory bowel disease in Germany. Pharmacoeconomics 2006;24(8):797-814
21. Bassi A, Dodd S, Williamson P, et al. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004;53(10):1471-8
22. Blomqvist P, Ekbom A. Inflammatory bowel diseases: health care and costs in Sweden in 1994. Scand J Gastroenterol 1997;32(11):1134-9
23. Hay JW, Hay AR. Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol 1992;14:309-17
24. Gibson TB, Ng E, Ozminkowski RJ, et al. The direct and indirect cost burden of Crohns disease and ulcerative colitis. J Occup Environ Med 2008;50(11):1261-72
25. Longobardi T, Jacobs P, Bernstein CN. Work losses related to IBD in the United States: results from the National Health Interview Survey. Am J Gastroenterol 2003;98:1064-72
26. Longobardi T, Jacobs P, Wu L, et al. Work losses related to inflammatory bowel disease in Canada: results from a National Population Health Survey. Am J Gastroenterol 2003;98(4):844-9
27. Lofland J, Naim A, Rizzo JA, et al. The indirect costs of inflammatory bowel disease: evidence from United States National Survey Data. Gastroenterology 2010; 138(5 Suppl 1):S317
28. Naim A, Nair KV, Van Den Bos J, et al. Comparison of total health care expenditures and absenteeism for inflammatory bowel disease from an employers perspective. Value Health 2010;3:A207
29. Van Der Valk ME, Mangen MJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFa therapy: results from the COIN study. Gut 2014;63(1):72-9
30. Cohen RD, Yu AP, Wu EQ, et al. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther 2010;31(7):693-707
31. Yu AP, Cabanilla LA, Wu EQ, et al. The costs of Crohns disease in the United States and other Western countries: a systematic review. Curr Med Res Opin 2008;24(2): 319-28
32. Odes S. How expensive is inflammatory bowel disease?. A critical analysis. World J Gastroenterol 2008;14(43):6641-7